AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Bill Tracker · Massachusetts

H3574

Concerning the use of a prescription medicine that contains 3,4-methylenedioxymethamphetamine (MDMA)

Status

Did not pass; died when the session ended

2024 Session

IntroducedMar 30, 2023 (done)
PassedDid not happen (skipped)
SignedDid not happen (skipped)
Law in effectDid not happen (skipped)

Sponsor: Nicholas Boldyga (Republican)
Type: Scheduling/Trigger Law
Substances: MDMA

Official text

Summary (from PoliPsy)

Relative to the use of a certain prescription medication used in psychotherapy and the treatment of post-traumatic stress disorder. Elder Affairs.

The full bill text and every version are kept by the legislature. We link to it rather than copy it so readers always see the current version.

Read the full bill text

Source: malegislature.gov

Legislative history

July 1, 2024
Accompanied a study order, see H4739
April 13, 2023
Referred
March 30, 2023
Referred
March 30, 2023
Introduced

Loading bill…